We’re proud to announce that Axol Bioscience has been named in the inaugural Sunday Times Scotland Fast 50, recognising some of the country’s fastest-growing businesses.
The Fast 50 celebrates Scottish companies achieving strong, sustainable growth across a broad range of sectors. Being included alongside such an inspiring and diverse group of organisations is a real honour for us and reflects the progress we’ve made as part of Scotland’s dynamic life sciences ecosystem.
This recognition is a testament to the dedication, passion, and expertise of our team, who work tirelessly to support our customers and advance iPSC research. Their commitment continues to drive innovation and impact in everything we do.
We’re also incredibly grateful to our customers and partners. Your trust and collaboration are central to our growth and success, and this achievement would not be possible without you.
We’re proud to be part of Scotland’s thriving community of ambitious, forward-thinking businesses and look forward to continuing this journey together.
At Axol Bioscience, we provide predictive, highly validated disease and safety models using human iPSC-derived cells, built from an extensive patient and donor-derived iPSC portfolio. We deliver scalable differentiation and manufacture of cryopreserved iPSC-derived cells alongside specialist discovery and preclinical services across four areas of research: neuroscience, ophthalmology, cardiovascular and dermatology.
